Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsNovartis AG ADR (NVS)
HKPD
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
$0.42
-0.12%
HEALTHCARE · Cap: $9.87M
NVS
Novartis AG ADR
$156.33
+0.29%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 421927% more annual revenue ($56.69B vs $13.43M). NVS leads profitability with a 22.5% profit margin vs -8.5%. NVS earns a higher WallStSmart Score of 51/100 (C-).
HKPD
Avoid26
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HKPD.
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$156.33
$63.60 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Safe zone — low bankruptcy risk
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -17.2% — below average capital efficiency
Revenue declined 31.7%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : HKPD
The strongest argument for HKPD centers on Price/Book, Altman Z-Score.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : HKPD
The primary concerns for HKPD are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
HKPD profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
HEALTHCARE · MEDICAL DISTRIBUTION · USA
Hong Kong Pharma Digital Technology Holdings Limited is a pioneering entity in the biotechnology and digital healthcare sectors, focused on enhancing patient outcomes through innovative pharmaceutical services. By harnessing cutting-edge digital technologies and sophisticated data analytics, the company optimizes drug development and boosts operational efficiencies, positioning itself as a key player in the dynamic healthcare landscape. With a commitment to health technology advancement and strategic collaborations, Hong Kong Pharma is well-equipped to meet the evolving needs of both domestic and international markets while propelling innovation within its extensive service offerings.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?